DiaMedica Ebitda vs Income Tax Expense Analysis
| DMAC Stock | USD 4.70 0.52 12.44% |
DiaMedica Therapeutics financial indicator trend analysis is much more than just examining DiaMedica Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether DiaMedica Therapeutics is a good investment. Please check the relationship between DiaMedica Therapeutics Ebitda and its Income Tax Expense accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.
Ebitda vs Income Tax Expense
Ebitda vs Income Tax Expense Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of DiaMedica Therapeutics Ebitda account and Income Tax Expense. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between DiaMedica Therapeutics' Ebitda and Income Tax Expense is -0.11. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of DiaMedica Therapeutics, assuming nothing else is changed. The correlation between historical values of DiaMedica Therapeutics' Ebitda and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of DiaMedica Therapeutics are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Ebitda i.e., DiaMedica Therapeutics' Ebitda and Income Tax Expense go up and down completely randomly.
Correlation Coefficient | -0.11 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Ebitda
Income Tax Expense
Most indicators from DiaMedica Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into DiaMedica Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.At present, DiaMedica Therapeutics' Tax Provision is projected to increase significantly based on the last few years of reporting.
| 2023 | 2024 (projected) | Reconciled Depreciation | 28K | 21.7K | Interest Income | 44.9K | 47.1K |
DiaMedica Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
DiaMedica Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
DiaMedica Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 9.1M | 28.1M | 45.6M | 34.4M | 54.2M | 56.9M | |
| Short Long Term Debt Total | 178K | 118K | 52K | 469K | 400K | 276.0K | |
| Other Current Liab | 1.1M | 791K | 917K | 1.3M | 1.7M | 1.8M | |
| Total Current Liabilities | 1.3M | 2.0M | 1.5M | 2.2M | 2.8M | 2.9M | |
| Total Stockholder Equity | 7.6M | 26.0M | 44.0M | 31.8M | 51.1M | 53.6M | |
| Property Plant And Equipment Net | 217K | 174K | 112K | 560K | 485K | 509.3K | |
| Net Debt | (3.7M) | (7.3M) | (4.7M) | (4.3M) | (4.1M) | (4.4M) | |
| Retained Earnings | (56.6M) | (68.9M) | (82.5M) | (96.2M) | (115.6M) | (109.8M) | |
| Accounts Payable | 182K | 1.1M | 509K | 734K | 926K | 563.1K | |
| Cash | 3.9M | 7.4M | 4.7M | 4.7M | 4.5M | 3.5M | |
| Non Current Assets Total | 217K | 174K | 112K | 560K | 485K | 638.8K | |
| Non Currrent Assets Other | 217K | 100K | (40.4M) | (1.0) | (0.9) | (0.94) | |
| Cash And Short Term Investments | 7.9M | 27.5M | 45.1M | 33.5M | 52.9M | 55.5M | |
| Net Receivables | 823K | 340K | 130K | 82K | 369K | 387.5K | |
| Common Stock Shares Outstanding | 12.0M | 15.7M | 20.8M | 26.4M | 32.6M | 34.2M | |
| Liabilities And Stockholders Equity | 9.1M | 28.1M | 45.6M | 34.4M | 54.2M | 56.9M | |
| Other Stockholder Equity | 64.2M | 94.9M | 126.6M | 128.1M | 166.6M | 174.9M | |
| Total Liab | 1.4M | 2.1M | 1.5M | 2.6M | 3.1M | 3.3M | |
| Property Plant And Equipment Gross | 217K | 174K | 179K | 560K | 585K | 614.3K | |
| Total Current Assets | 8.8M | 27.9M | 45.4M | 33.8M | 53.7M | 56.4M | |
| Accumulated Other Comprehensive Income | 2K | (2K) | (51K) | (74K) | 6K | 5.7K | |
| Short Term Debt | 60K | 130K | 98K | 138K | 166K | 90.0K | |
| Other Current Assets | 47K | 74K | 197K | 251K | 411K | 431.6K | |
| Net Tangible Assets | 17.0M | 7.6M | 26.0M | 44.0M | 50.6M | 53.2M | |
| Short Term Investments | 4.0M | 20.1M | 40.4M | 28.8M | 48.4M | 50.8M | |
| Property Plant Equipment | 217K | 74K | 112K | 560K | 644K | 676.2K | |
| Capital Surpluse | 41.0M | 63.0M | 64.2M | 94.9M | 109.2M | 114.6M | |
| Non Current Liabilities Total | 118K | 53K | 3K | 400K | 317K | 158.5K | |
| Capital Lease Obligations | 178K | 118K | 52K | 469K | 400K | 420K | |
| Net Invested Capital | 7.6M | 26.0M | 44.0M | 31.8M | 51.1M | 28.0M | |
| Net Working Capital | 7.5M | 25.9M | 43.9M | 31.7M | 50.9M | 27.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.56) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.